Colorado researchers discovered that nearly half of tested cannabis flower products exaggerated their THC levels, while concentrates were mostly accurate. The team’s statewide audit revealed potency inconsistencies that could mislead consumers and affect safe dosing. Beyond THC, the study also found that cannabinoids like CBG and CBGA are underreported. The findings may help shape future regulations and improve consumer trust in the growing cannabis market.
